Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
SLCO1B1 10599 CLARITHROMYCIN CHEMBL1741 DrugBank 23571415
SLCO1B1 10599 ATORVASTATIN CHEMBL1487 NCI 17192770
SLCO1B1 10599 DOCETAXEL CHEMBL92 NCI 16210916
SLCO1B1 10599 CYTARABINE CHEMBL803 PharmGKB
SLCO1B1 10599 PITAVASTATIN CHEMBL1201753 PharmGKB
SLCO1B1 10599 CERIVASTATIN CHEMBL1477 PharmGKB
SLCO1B1 10599 BOSENTAN CHEMBL957 PharmGKB
SLCO1B1 10599 METHOTREXATE CHEMBL34259 CIViC 23652803
SLCO1B1 10599 LOVASTATIN CHEMBL503 PharmGKB
SLCO1B1 10599 VALSARTAN CHEMBL1069 PharmGKB
SLCO1B1 10599 ATRASENTAN CHEMBL9194 PharmGKB
SLCO1B1 10599 REPAGLINIDE CHEMBL1272 PharmGKB
SLCO1B1 10599 PYRAZINAMIDE CHEMBL614 PharmGKB
SLCO1B1 10599 ISONIAZID CHEMBL64 PharmGKB
SLCO1B1 10599 LOPINAVIR CHEMBL729 PharmGKB
SLCO1B1 10599 CYCLOSPORINE CHEMBL160 inhibitor GuideToPharmacologyInteractions
SLCO1B1 10599 PRAVASTATIN CHEMBL1144 GuideToPharmacologyInteractions, NCI 16678544
SLCO1B1 10599 ETHAMBUTOL HYDROCHLORIDE CHEMBL1628240 PharmGKB
SLCO1B1 10599 ROSUVASTATIN CHEMBL1496 FDA
SLCO1B1 10599 GEMTUZUMAB OZOGAMICIN CHEMBL1201506 PharmGKB
SLCO1B1 10599 GLYCYRRHIZIN CHEMBL441687 inhibitor GuideToPharmacologyInteractions
SLCO1B1 10599 ARSENIC CHEMBL1231052 PharmGKB
SLCO1B1 10599 GEMFIBROZIL CHEMBL457 inhibitor GuideToPharmacologyInteractions, NCI 16316932
SLCO1B1 10599 FENOFIBRATE CHEMBL672 NCI 16316932
SLCO1B1 10599 RIFAMPICIN CHEMBL374478 inhibitor GuideToPharmacologyInteractions, DrugBank 12085361
SLCO1B1 10599 CLOFIBRATE CHEMBL565 NCI 16316932
SLCO1B1 10599 TROGLITAZONE CHEMBL408 PharmGKB, NCI 14977862

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
SLCO1B1 rs4149056 C atorvastatin metabolism/PK yes Allele C is associated with increased exposure to atorvastatin as compared to allele T. 32128760 1451163180
SLCO1B1 rs4149056 C rifampin metabolism/PK no No significant difference in rifampin AUC between genotype groups. Variant referred to in the paper as c.521T>C. Allele C is not associated with exposure to rifampin in men as compared to allele T. 19374892 1451163505
SLCO1B1 rs4149056 CC + CT rosuvastatin efficacy no SLCO1B1 521T > C was not significantly associated with the LDL-c response to rosuvastatin. Genotypes CC + CT are not associated with response to rosuvastatin as compared to genotype TT. 31857620 1451164700
SLCO1B1 rs4149056 CC + CT atorvastatin metabolism/PK yes Genotypes CC + CT are associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT. 31594719 1451164960
SLCO1B1 rs2306283 AA + AG atorvastatin metabolism/PK no Genotypes AA + AG are not associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype GG. 31594719 1451164966
SLCO1B1 SLCO1B1*1, SLCO1B1*15 *15 atorvastatin metabolism/PK yes patients carrying at least one SLCO1B1*15 allele (i.e. *1a/*15, *1b/*15, *15/*15) tended have higher AUC than that in non-*15 carriers (i.e.*1a/*1a, *1a/*1b and *1b/*1b). The difference in AUC was significant only after its microdose, but not at therapeutic dose. SLCO1B1 *15 is associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1. 31594719 1451165020
SLCO1B1 rs4149056 CC + CT atorvastatin metabolism/PK yes Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT. 29442027 1451230062
SLCO1B1 rs4149056 CC + CT atorvastatin efficacy no This variant is not significantly associated with atorvastatin response. However, the carriers of c.521CC manifested a lower decrease in plasma levels of TG, TC, LDL-C and Lp(a), with percentage difference being 16 %, 7 %, 29 % and 149 %, respectively, compared to the carriers of c.521TT variant. Genotypes CC + CT are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT. 29441875 1451230320
SLCO1B1 rs2306283 AG + GG atorvastatin efficacy no This variant is not significantly associated with atorvastatin response. Genotypes AG + GG are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA. 29441875 1451230340
SLCO1B1 SLCO1B1*1, SLCO1B1*15 *15 atorvastatin efficacy no This haplotype is not significantly associated with atorvastatin response. SLCO1B1 *15 is not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1. 29441875 1451230380
SLCO1B1 rs4149056 CC + CT pravastatin metabolism/PK yes Genotypes CC + CT are associated with increased concentrations of pravastatin in children with Hypercholesterolemia as compared to genotype TT. 30549267 1451226263
SLCO1B1 SLCO1B1*1, SLCO1B1*15 *15/*15 atorvastatin metabolism/PK not stated SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15. 30528195 1451226420
SLCO1B1 SLCO1B1*1, SLCO1B1*15 *15/*15 pitavastatin metabolism/PK not stated SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15. 30528195 1451226403
SLCO1B1 SLCO1B1*1, SLCO1B1*15 *15/*15 fluvastatin metabolism/PK not stated SLCO1B1 *15/*15 is not associated with increased concentrations of fluvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15. 30528195 1451226441
SLCO1B1 SLCO1B1*1, SLCO1B1*15 *15/*15 rosuvastatin metabolism/PK not stated SLCO1B1 *15/*15 is associated with increased concentrations of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15. 30528195 1451226461
SLCO1B1 rs4149056 TT simvastatin efficacy yes Patients carrying 521TT genotype had greater TC and LDL-C reduction in response to simvastatin after 4 weeks of treatment. Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT. 30336686 1451226960
SLCO1B1 rs2306283 AG + GG simvastatin efficacy no Patients carrying 388G allele alone is not significantly associated with greater TC and LDL-C reduction in response to simvastatin after 4 weeks of treatment. no significant associations were found between the 521T>C and 388A>G polymorphisms and the lipid-lowering effects of simvastatin treatment after 8 weeks. Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA. 30336686 1451227020
SLCO1B1 rs4149056 CC + CT rosuvastatin metabolism/PK no SLCO1B1 521T>C (rs4149056) in patients with one or two copies of the variant allele had a significantly high plasma exposure to RST, whereas the significance was not found after multiple testing (Padj = 0.0247, FDR = 0.0988), Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT. 29950617 1451228580
SLCO1B1 rs4149056 CC + CT simvastatin efficacy no There was no association between this variant and lipid-lowering response to 3 and 12 months of20 mg/day simvastatin treatment. Genotypes CC + CT are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype TT. 29575099 1451228860
SLCO1B1 rs2306283 AG + GG simvastatin efficacy no There was no association between this variant and lipid-lowering response to 3 and 12 months of20 mg/day simvastatin treatment. Genotypes AG + GG are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype AA. 29575099 1451228880
SLCO1B1 rs4363657 CC + CT simvastatin efficacy no There was no association between this variant and lipid-lowering response to 3 and 12 months of20 mg/day simvastatin treatment. Genotypes CC + CT are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype TT. 29575099 1451228900
SLCO1B1 rs4149056 C simvastatin metabolism/PK yes Patients were followed for 6 weeks (40 mg simvastatin at bedtime) and seen at the clinic at 2 week intervals. Patients with the CT and CC genotypes had 71% and 248% higher plasma simvastatin acid at 12 hours, respectively, as compared to those with the TT genotypes. In a separate analysis, the authors combined patients into groups based on their expected simvastatin acid/ simvastatin ratios (SVA/SV). The groups were low, intermediate, or high. The high and medium SVA/SV group included carriers of the C allele. There was a significant difference in 12 hr plasma SVA/SV ratios between the low, intermediate, and high SVA/SV ratio genotype groups Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T. 26164721 1446896983
SLCO1B1 rs4149056 CC simvastatin acid metabolism/PK yes AUC increased 171% in CC individuals. Study participants received 40 mg simvastatin, followed by a second 40 mg dose 24 hours later. Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT. 25446771 1447983120
SLCO1B1 rs4149056 CT pravastatin efficacy yes Patients with the CT genotype had greater increases in HDL cholesterol but smaller decreases in total cholesterol and LDL cholesterol. This variant was described as 521T>C. Genotype CT is associated with increased response to pravastatin in children with Transplantation as compared to genotype TT. 16722833 982043181
SLCO1B1 rs4149056 CT simvastatin metabolism/PK no Genotype CT is not associated with increased exposure to simvastatin as compared to genotype TT. 28350522 1448612598
SLCO1B1 rs4149056 CT pravastatin efficacy yes as determined by a smaller reduction in total cholestrol in patients with the CT genotype compared to the TT genotype. Changes in LDL-C, HDL-C and triglycerides were not significantly different. Genotype CT is associated with decreased response to pravastatin in people with Coronary Stenosis as compared to genotype TT. 17439540 982043772
SLCO1B1 rs4149056 TT fluvastatin efficacy yes as measured by increases in HDL-cholestrol. Genotype TT is associated with increased response to fluvastatin as compared to genotypes CC + CT. 16103896 982045631
SLCO1B1 rs4149056 C methotrexate "efficacy","toxicity","metabolism/PK" yes Average clearance was about 13% lower in CC than in TT patients. Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. 23233662 981483656
SLCO1B1 rs2306283 A methotrexate "efficacy","toxicity","metabolism/PK" yes This association was found in patients already stratified for rs4149056 genotype. Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G. 23233662 981483665
SLCO1B1 rs11045879 C methotrexate "efficacy","toxicity","metabolism/PK" yes Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. 23233662 981483686
SLCO1B1 rs4149081 A methotrexate "efficacy","toxicity","metabolism/PK" yes Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G. 23233662 981483693
SLCO1B1 rs4149015 AG pravastatin metabolism/PK yes 2 patients with the AG genotype (who also had rs4149056 genotype TC) had significantly higher increases in HDL-cholesterol after treatment. Genotypes were not associated with lipid-lowering effect. This variant was described as -11187G>A. Genotype AG is associated with increased response to pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype GG. 16722833 982043138
SLCO1B1 rs4149056 CT pravastatin metabolism/PK no No significant association was found with this SNP, though there was a trend for lower plasma concentrations in patients with the CT genotype. This variant was described as 521T>C. Genotype CT is not associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype TT. 16722833 982043146
SLCO1B1 rs4149056 CC + CT methotrexate metabolism/PK yes With each C allele, the area under the concentration time curve (AUC0-48h) of methotrexate increased by 26%, the peak plasma concentration at end of infusion (C24) increased by 24% and clearance decreased by 18%. Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT. 23652803 1183681696
SLCO1B1 rs2306283 AA + AG methotrexate metabolism/PK yes The A allele is related to decreased area under the concentration time curve (AUC0-48h) of and increased clearance of methotrexate. Genotypes AA + AG are associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. 23652803 1183681703
SLCO1B1 SLCO1B1*15, SLCO1B1*1A, SLCO1B1*5 *5/*15 + *15/*15 lovastatin acid metabolism/PK yes Please note the association is for lovastatin acid the active metabolite of lovastatin. Geometric mean Cmax and AUC0–24 of lovastatin acid were 340 and 286% for *5/*15 and *15/*15 carrier. Lovastatin acid to lovastatin AUC0–24 ratio was 239% higher. SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1A/*1A. 26020121 1444713578
SLCO1B1 rs4149056 CC simvastatin acid metabolism/PK yes SLCO1B1 polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT. 17108811 1451249860
SLCO1B1 SLCO1B1*1A, SLCO1B1*1B, SLCO1B1*5 *5 methotrexate metabolism/PK yes SLCO1B1 *5 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1A + *1B. 22147369 1184747012
SLCO1B1 SLCO1B1*15, SLCO1B1*1A, SLCO1B1*1B *15 methotrexate metabolism/PK yes SLCO1B1 *15 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1A + *1B. 22147369 1184747027
SLCO1B1 rs4149056 CC + CT efavirenz metabolism/PK no Genotypes CC + CT are not associated with concentrations of efavirenz in children with HIV Infections as compared to genotype TT. 28718515 1448821794
SLCO1B1 rs4149056 CC methotrexate efficacy yes Evidence of minimal residual disease at 78 days was higher in CC genotype vs. CT + TT. Genotype CC is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT. 28525903 1449002901
SLCO1B1 rs11045879 C methotrexate efficacy no Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. 28525903 1449002940
SLCO1B1 rs2306283 G methotrexate efficacy no Please note: alleles have been complemented to the + chromosomal strand. Allele G is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A. 28525903 1449002964
SLCO1B1 rs11045879 CC + CT methotrexate metabolism/PK no There is no association between selected SNPs and methotrexate plasma level at 48 h between the first dose of methotrexate infusion. med. MTX concentration: CC +TC (0.50 (0.09–41.63)) vs. TT(0.39 (0.12–19.88)) Genotypes CC + CT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT. 28525903 1449003329
SLCO1B1 rs4149056 CT + TT methotrexate metabolism/PK no There is no association between selected SNPs and methotrexate plasma level at 48 h between the first dose of methotrexate infusion. med. MTX concentration: TC+TT (0.45 (0.09–41.63)) vs. CC 1.1. (0.15–7.53)). Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. 28525903 1449003337
SLCO1B1 rs10841753 CT + TT methotrexate metabolism/PK yes There is an association between selected SNPs and methotrexate plasma level at 48 h between the first dose of methotrexate infusion. med. MTX concentration: CT+TT (0.47 (0.09–41.63)) vs. CC 0.32 (0.14–5.50)). Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. 28525903 1449003343
SLCO1B1 rs2306283 AG + GG methotrexate metabolism/PK no There is no association between selected SNPs and methotrexate plasma level at 48 h between the first dose of methotrexate infusion. med. MTX concentration: GG+AG (0.45 (0.09–41.63)) vs. AA (0.37 (0.12–3.91)). Please note: alleles have been complemented to the + chromosomal strand. Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA. 28525903 1449003438
SLCO1B1 rs10841753 C methotrexate efficacy no Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. 28525903 1449003454
SLCO1B1 rs4149056 CC + CT simvastatin acid metabolism/PK yes Cmax for CC patients = 2.1ng/ml, Cmax for CT patients = 1.0ng/ml, Cmax for TT patients = 0.4ng/ml. AUC of simvastatin acid in CC patients was 6.3 fold higher than the AUC of simvastatin acid in TT patients. The AUC in CT patients was 2.4 fold higher than in CC patients. Genotypes CC + CT are associated with increased concentrations of simvastatin acid in children as compared to genotype TT. 29469964 1449556752
SLCO1B1 rs2306283 G lopinavir metabolism/PK no No association between this variant and AUC0-12 of lopinavir or ritonavir in patients treated with lopinavir/ritonavir. Variant referred to in the paper as A388G. Allele G is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele A. 21743379 1451114883
SLCO1B1 rs4149056 CT lopinavir metabolism/PK yes Patients with the CT genotype had a significantly increased AUC0-12 of lopinavir compared to the TT genotype in patients treated with lopinavir/ritonavir. Variant referred to in the paper as T512C. Genotype CT is associated with increased exposure to lopinavir in children with HIV Infections as compared to genotype TT. 21743379 1451114889
SLCO1B1 rs4149056 C ritonavir metabolism/PK no No significant association between this variant and ACU0-12 of ritonavir in patients treated with lopinavir/ritonavir. Variant referred to in the paper as T512C. Allele C is not associated with exposure to ritonavir in children with HIV Infections as compared to allele T. 21743379 1451114894
SLCO1B1 rs2306283 G lopinavir metabolism/PK no No association between this variant and virologic suppression in patients treated with lopinavir/ritonavir. Variant referred to in the paper as A388G. Allele G is not associated with response to lopinavir or ritonavir in children with HIV Infections as compared to allele A. 21743379 1451114900
SLCO1B1 rs2306283 G lopinavir metabolism/PK no No association between this variant and clearance of lopinavir or ritonavir in patients treated with lopinavir/ritonavir. Variant referred to in the paper as A388G. Allele G is not associated with clearance of lopinavir or ritonavir in children with HIV Infections as compared to allele A. 21743379 1451114920
SLCO1B1 rs4149056 C lopinavir metabolism/PK no No significant association between this variant and virologic suppression in patients treated with lopinavir/ritonavir. Variant referred to in the paper as T512C. Allele C is not associated with response to lopinavir or ritonavir in children with HIV Infections as compared to allele T. 21743379 1451114925
SLCO1B1 rs4149056 C ritonavir metabolism/PK no No significant association between this variant and clearance of ritonavir in patients treated with lopinavir/ritonavir. Variant referred to in the paper as T512C. Allele C is not associated with clearance of ritonavir in children with HIV Infections as compared to allele T. 21743379 1451114966
SLCO1B1 rs4149015 AG pravastatin metabolism/PK yes 2 patients with the AG genotype (who also had rs4149056 genotype TC) had significantly lower plasma Cmax and AUC. This variant was described as -11187G>A. Genotype AG is associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype GG. 16722833 982043099
SLCO1B1 SLCO1B1*15 *15/*15 rosuvastatin metabolism/PK yes Those with the *15/*15 genotype had increased exposure to the drug, as determined by higher AUC0-infinity values and higher maximum plasma concentrations. The study genotyped for rs2306283 (388A>G) and rs4149056 (521T>C) in OATP1B1 (SLCO1B1) - rsIDs not provided. SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1A/*1A. 17568401 982043792
SLCO1B1 SLCO1B1*15 *15/*15 rosuvastatin metabolism/PK yes Those with the *15/*15 genotype had increased exposure to the drug, as determined by higher AUC0-infinity values and higher maximum plasma concentrations. The study genotyped for rs2306283 (388A>G) and rs4149056 (521T>C) in OATP1B1 (SLCO1B1) - rsIDs not provided. SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1B/*15. 17568401 982043808
SLCO1B1 rs4149056 CC + CT hmg coa reductase inhibitors efficacy yes Subjects with the 521C allele showed an attenuated total-cholesterol-lowering effect compared with those homozygous for the 521T allele (-22.3+/-8.7% vs. -16.5+/-10.5%, p<0.05). Drugs included: pravastatin, atorvastatin, and simvastatin. Genotypes CC + CT are associated with decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to genotype TT. 15548849 1451256960
SLCO1B1 rs34671512 C rosuvastatin metabolism/PK yes Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele A. 30100615 1449733067
SLCO1B1 rs12305884 A rosuvastatin metabolism/PK yes Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G. 30100615 1449733045
SLCO1B1 rs11045821 A methotrexate "efficacy","toxicity","metabolism/PK" yes Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G. 23233662 981483700
SLCO1B1 rs4149056 C pravastatin metabolism/PK not stated Subjects caring the C allele as part of the OATP-C*15 allele (Asp130Ala174) had a reduced total and nonrenal clearance, as compared with those with the OATP-C*1b allele (Asp130Val174) (T allele). Allele C is associated with decreased metabolism of pravastatin in healthy individuals as compared to allele T. 12811365 769170865
SLCO1B1 rs4149034 A methotrexate metabolism/PK no Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G. 29791011 1450045193
SLCO1B1 rs2900476 C methotrexate metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T. 29791011 1450045199
SLCO1B1 rs1463565 C methotrexate metabolism/PK no Based on the MAF given in the paper, it is assumed that these alleles are reported as being on the positive strand. Therefore, they have not been complemented in this annotation. Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G. 29791011 1450045211
SLCO1B1 rs4149026 C methotrexate metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A. 29791011 1450045217
SLCO1B1 rs2417955 A methotrexate metabolism/PK no Based on the MAF given in the paper, it is assumed that these alleles are reported as being on the positive strand. Therefore, they have not been complemented in this annotation. Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T. 29791011 1450045223
SLCO1B1 rs4149035 T methotrexate metabolism/PK no Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C. 29791011 1450045229
SLCO1B1 rs10444413 C methotrexate metabolism/PK no Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T. 29791011 1450045235
SLCO1B1 SLCO1B1*15, SLCO1B1*1B *1B/*15 repaglinide metabolism/PK yes SLCO1B1 *1B/*15 is associated with increased concentrations of repaglinide in healthy individuals as compared to SLCO1B1 *1B/*1B. 29748863 1449311397
SLCO1B1 SLCO1B1*15, SLCO1B1*1A, SLCO1B1*1B *1A/*15 repaglinide metabolism/PK yes SLCO1B1 *1A/*15 is associated with increased concentrations of repaglinide in healthy individuals as compared to SLCO1B1 *1B/*1B. 29748863 1449311388
SLCO1B1 SLCO1B1*15, SLCO1B1*1A, SLCO1B1*1B *1B/*15 repaglinide metabolism/PK yes SLCO1B1 *1B/*15 is associated with increased concentrations of repaglinide in healthy individuals as compared to SLCO1B1 *1A/*1B. 29748863 1449311379
SLCO1B1 rs58310495 T fluvastatin metabolism/PK yes This variant is significantly associated with increased area under the plasma concentration-time curve (AUC) of 3R,5S-fluvastatin, but not 3S,5R-fluvastatin. The AUC was 34% larger per copy of the variant allele. This variant is strongly linked with SLCO1B1 c.521T>C (r2=0.69). Allele T is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele C. 30989645 1450823491
SLCO1B1 SLCO1B1*15, SLCO1B1*16, SLCO1B1*17, SLCO1B1*1A, SLCO1B1*5 *5 + *15 + *16 + *17 rosiglitazone metabolism/PK no There were no significant differences in rosiglitazone pharmacokinetic parameters between SLCO1B1 diplotype groups. SLCO1B1 *5 + *15 + *16 + *17 are not associated with concentrations of rosiglitazone in healthy individuals as compared to SLCO1B1 *1A/*1A. 19129086 1450935228
SLCO1B1 rs11045872 G methotrexate "efficacy","toxicity","metabolism/PK" no Allele G is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma. 23233662 981483674
SLCO1B1 rs2306283 AA pravastatin efficacy no as measured by decreases in LDL-cholestrol. No significant association was seen between all three genotypes and response. Genotype AA is not associated with response to pravastatin as compared to genotype GG. 16103896 982045832
SLCO1B1 rs11045819 A lopinavir metabolism/PK no Although the A allele was initially found to be significantly associated with decreased trough concentrations of lopinavir, this significance was lost following multivariate regression analysis. Allele A is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele C. 32022294 1451116362
SLCO1B1 rs4149056 C lopinavir metabolism/PK yes Association was significant in white patients only. Only 1/31 black patients and 1/17 Hispanic patients carried the C allele, so statistical analysis could not be carried out. However, the authors note that these patients had amongst the highest trough concentrations of lopinavir. Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T. 23503447 1451115303
SLCO1B1 rs4149032 T lopinavir metabolism/PK no Although the T allele was initially found to be significantly associated with decreased trough concentrations of lopinavir, this significance was lost following multivariate regression analysis. Allele T is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele C. 32022294 1451116369
SLCO1B1 rs2291073 GT + TT lovastatin efficacy yes as measured by decreases in triglycerides seen in patients with the GT or TT genotype, but decreases were not seen in those with the GG genotype. Genotypes GT + TT are associated with increased response to lovastatin as compared to genotype GG. 16103896 982045579
SLCO1B1 rs4149036 AC + CC atorvastatin efficacy yes as measured by decreases in triglycerides. Genotypes AC + CC are associated with increased response to atorvastatin as compared to genotype AA. 16103896 982045547
SLCO1B1 SLCO1B1*15 *15 olmesartan metabolism/PK yes Apparent total clearance (CLt/F) was significantly lower in patients homozygous for the *15 allele as compared to patients homozygous for the *1B allele. This may be due to a change in F rather than a change in CLt, but cannot be verified as the study did not obtain intravenous data to estimate bioavailability. It is also of note that this study determined that olmesartan likely does not have an effect on the pharmacokinetics of pravastatin or its metabolite, RMS-416. SLCO1B1 *15 is associated with decreased clearance of olmesartan in healthy individuals as compared to SLCO1B1 *1B. 18641915 1043858738
SLCO1B1 SLCO1B1*15 *15/*15 rosuvastatin metabolism/PK yes Those with the *15/*15 genotype had increased exposure to the drug, as determined by higher AUC0-infinity values and higher maximum plasma concentrations. Cmax was significantly higher p=0.0389, AUC was not. The study genotyped for rs2306283 (388A>G) and rs4149056 (521T>C) in OATP1B1 (SLCO1B1) - rsIDs not provided. SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1B/*1B. 17568401 982043801
SLCO1B1 rs4149056 CC pravastatin efficacy no as measured by decreases in LDL-cholestrol. No significant association was seen between all three genotypes and response. Genotype CC is not associated with response to pravastatin as compared to genotype TT. 16103896 982045915
SLCO1B1 SLCO1B1*1A, SLCO1B1*1B, SLCO1B1*31 *31 methotrexate metabolism/PK yes SLCO1B1 *31 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1A + *1B. 22147369 1184747049
SLCO1B1 SLCO1B1*14, SLCO1B1*1A, SLCO1B1*1B *14 methotrexate metabolism/PK yes SLCO1B1 *14 is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1A + *1B. 22147369 1184747060
SLCO1B1 rs4149056 CC axitinib metabolism/PK no No association was found between this SNP and metabolism of axitinib. This meta-analysis included 11 phase I clinical trials. Genotype CC is not associated with metabolism of axitinib in healthy individuals as compared to genotypes CT + TT. 22170007 1183697477
SLCO1B1 rs11045819 AC rifampin metabolism/PK not stated Lower Cmax concentrations of rifampin were observed in individuals with the AC genotype. Genotype AC is associated with increased clearance of rifampin in healthy individuals as compared to genotype CC. 24420746 1183704875
SLCO1B1 SLCO1B1*1A, SLCO1B1*1B, SLCO1B1*35 *35 methotrexate metabolism/PK yes SLCO1B1 *35 is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1A + *1B. 22147369 1184747071
SLCO1B1 rs2306283 GG rifampin metabolism/PK not stated Higher Cmax concentrations of rifampin were observed in individuals with the GG genotype. Genotype GG is associated with decreased clearance of rifampin in healthy individuals as compared to genotypes AA + AG. 24420746 1183704865
SLCO1B1 rs4149056 CC + CT rosuvastatin metabolism/PK yes This variant affected rosuvastatin concentration significantly and potentially affect serum levels of pro-inflammatory and pro-angiogenic markers. Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT. 32361904 1451141460
SLCO1B1 SLCO1B1*15, SLCO1B1*1A *1A/*15 repaglinide metabolism/PK yes SLCO1B1 *1A/*15 is associated with increased concentrations of repaglinide in healthy individuals as compared to SLCO1B1 *1A/*1A. 29748863 1449311336
SLCO1B1 SLCO1B1*1A, SLCO1B1*1B, SLCO1B1*23 *23 methotrexate metabolism/PK yes SLCO1B1 *23 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1A + *1B. 22147369 1184747038
SLCO1B1 SLCO1B1*14, SLCO1B1*1A *14 fluvastatin efficacy yes Patients with the c.463A (*14 allele) had greater percentage LDL-C reduction from baseline (p = 0.005) and with mean post-treatment LDL-C values (p = 0.0005). SLCO1B1 *14 is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1A. 18781850 1184748435
SLCO1B1 rs4149056 CC + CT ritonavir metabolism/PK yes Ritonavir peripheral blood mononuclear cell (PBMC) intracellular trough concentrations were higher for those with the CT or CC genotype, as compared to those with the TT genotype. The same trend was observed for ritonavir plasma concentrations, but did not reach statistical significance. Additionally, note that this allele was not significantly associated with intracellular concentrations when using univariate or multivariate linear regression analysis (p=0.091 and 0.866, respectively). Genotypes CC + CT is associated with increased concentrations of ritonavir in people with HIV Infections as compared to genotype TT. 24997317 1184748352
SLCO1B1 rs2306283 AA atorvastatin efficacy yes Response measured as reduction of LDL-C after 8 weeks of treatment with 10mg/day of atorvastatin. Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG. 26932749 1447949678
SLCO1B1 rs4149056 CC + CT simvastatin efficacy yes Patients treated with simvastatin and harbouring the SLCO1B1 521C allele were less likely to achieve the treatment goal at the 5-year follow-up. Genotypes CC + CT is associated with decreased response to simvastatin in people with Dyslipidaemia as compared to genotype TT. 25379722 1184998473
SLCO1B1 rs4149056 C simvastatin acid metabolism/PK yes Increased AUC of simvastatin acid are found in C allele carriers. Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT. 26367500 1446907580
SLCO1B1 rs2306283 GG atazanavir metabolism/PK no Looked at CL/F, Concentration at 24 hours, ratios of metabolites 1 and 2 to atazanavir. Genotype GG (assigned as deficiency phenotype) is not associated with concentrations of atazanavir in people with HIV Infections as compared to genotypes AA + AG. 26892777 1447947654
SLCO1B1 rs4149056 CT atazanavir metabolism/PK no Looked at CL/F, concentration at 24 hours, and ratios of metabolites M1 and M2 to atazanavir. No CC genotypes identified. Genotype CT (assigned as deficiency phenotype) is not associated with concentrations of atazanavir in people with HIV Infections as compared to genotype TT. 26892777 1447947662
SLCO1B1 rs4149056 CC + CT atorvastatin efficacy no No significant differences in percent change between the genotypes for total cholesterol (p=0.58), high-density lipoprotein cholesterol (HDL-C; p=0.15), low-density lipoprotein cholesterol (LDL-C; p=0.34) or triglycerides (p=0.92). Patients were treated with atorvastatin for 4 weeks at 10 mg/day. Genotypes CC + CT is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT. 26334272 1446896334
SLCO1B1 rs2306283 AG + GG atorvastatin efficacy yes Patients with the AG and GG genotype had a greater percent increase in high-density lipoprotein cholesterol (HDL-C) levels as compared to those with the AA genotype. However, no significant differences in percent changes between genotypes were seen for total cholesterol (p=0.81), low density lipoprotein cholesterol (LDL-C; p=0.27) or triglycerides (p=0.30). Patients were treated with atorvastatin for 4 weeks at 10 mg/day. Genotypes AG + GG is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA. 26334272 1446896327
SLCO1B1 rs4149056 C hmg coa reductase inhibitors efficacy yes as measured by plasma LDL-c. Allele C is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T. 25916517 1447943994
SLCO1B1 rs4149045 AG + GG lopinavir metabolism/PK no Genotypes AG + GG is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype AA. 27142945 1447986129
SLCO1B1 rs4149057 CC + CT lopinavir metabolism/PK no Genotypes CC + CT is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype TT. 27142945 1447986136
SLCO1B1 rs4149044 AA + AT lopinavir metabolism/PK no Genotypes AA + AT is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype TT. 27142945 1447986122
SLCO1B1 rs4149056 C lopinavir metabolism/PK no because this variant was monomorphic in this population. Allele C is not associated with concentrations of lopinavir in people with HIV Infections. 27142945 1447986096
SLCO1B1 rs4149056 CT atorvastatin metabolism/PK not stated 1) Caucasians AUC0-t (ng*h/mL): Geometric mean (95% CI) AND Cmax (ng/mL): Geometric mean (95% CI) 2) Chinese AUC0-t (ng*h/mL): Geometric mean (95% CI) AND Cmax (ng/mL): Geometric mean (95% CI) 3) Japanese AUC0-t (ng*h/mL): Geometric mean (95% CI) AND Cmax (ng/mL): Geometric mean (95% CI) Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT. 25673568 1447990018
SLCO1B1 rs4149056 T ticagrelor metabolism/PK yes Alleles given as A/G. Part of a GWAS study with replication cohort. This study did not find changes in primary outcomes on ticagrelor, but did find differences in AUC of ticagrelor and the metabolite ARC (AR-C124910XX). Significantly associated with AUC in the discovery phase, replication phase, and combined. Allele T is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele C. 25935875 1447987282
SLCO1B1 rs113681054 C ticagrelor metabolism/PK yes GWAS study. Does not specifically say which allele was associated with directionality of concentration. Minor allele found on dbSNP. This study did not find changes in primary outcomes on ticagrelor, but did find differences in AUC of ticagrelor and the metabolite ARC (AR-C124910XX). Allele C is associated with increased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele T. 25935875 1447987275
SLCO1B1 rs4149056 TT atazanavir metabolism/PK no Genotype TT is not associated with clearance of atazanavir in healthy individuals as compared to genotypes CC + CT. 22394315 1448617452
SLCO1B1 rs4149056 CT rifampin metabolism/PK yes Genotype CT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotype TT. 28594304 1448632071
SLCO1B1 rs113681054 CT ticagrelor efficacy no No difference between any of the genotype groups. Genotype CT is not associated with response to ticagrelor in healthy individuals as compared to genotypes CC + TT. 28049954 1448531954
SLCO1B1 rs4149056 CT simvastatin acid metabolism/PK yes This variant significantly increased exposure to simvastatin acid (but not simvastatin) by around 40% (p < 0.05), similar to that caused by the amlodipine pretreatment. Genotype CT is associated with increased exposure to simvastatin acid as compared to genotype TT. 28350522 1448612369
SLCO1B1 rs4149056 CC rosuvastatin metabolism/PK yes This effect was only seen in the subset of white individuals, and not observed in the different groups of Asian individuals where there were no CC homozygotes. Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT. 16198652 1449733005
SLCO1B1 rs4149056 TT conjugated estrogens metabolism/PK yes Genotype TT is associated with decreased concentrations of conjugated estrogens in women with Menopause as compared to genotypes CC + CT. 29738412 1449311424
SLCO1B1 rs4149056 CT conjugated estrogens efficacy yes Women with the CT genotype had a significantly increased reduction in night sweats following hormonal therapy than women with the TT genotype. Genotype CT is associated with increased response to conjugated estrogens in women with Menopause as compared to genotype TT. 29738412 1449311435
SLCO1B1 SLCO1B1*15, SLCO1B1*1A, SLCO1B1*1B *1A/*15 repaglinide metabolism/PK yes SLCO1B1 *1A/*15 is associated with increased concentrations of repaglinide in healthy individuals as compared to SLCO1B1 *1A/*1B. 29748863 1449311359
SLCO1B1 SLCO1B1*15, SLCO1B1*1A, SLCO1B1*1B *1B/*15 repaglinide metabolism/PK yes SLCO1B1 *1B/*15 is associated with increased concentrations of repaglinide in healthy individuals as compared to SLCO1B1 *1A/*1A. 29748863 1449311348
SLCO1B1 rs4149056 TT glucose metabolism/PK yes who are co-administered repaglinide and irbesartan. Glucose minimum concentration, and area under the concentration curve 0-3hr, and 0-8hrs, were all different between subjects given repaglinide alone, or with irbesartan. Genotype TT is associated with concentrations of glucose in healthy individuals. 29748863 1449311453
SLCO1B1 rs4149056 CC + CT mercaptopurine dosage yes Patients with the CC+CT genotype tolerated a median mercaptopurine dose of 31.7 (mg/sq.m/day) vs 41 (mg/sq.m/d) for the TT genotypes and a median methotrexate dose of 9.4 (mg/sq.m/wk) vs 11.9 (mg/sq.m/wk). This SNP was in high L.D. with rs11045879. Genotypes CC + CT is associated with decreased dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT. 29683944 1449311153
SLCO1B1 rs4149056 T tacrolimus metabolism/PK no This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients. Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. 29318894 1449163284
SLCO1B1 rs11045854 A rosuvastatin metabolism/PK yes Text describes Alleles 882A as 75% reduced exposure. Table 2 lists this A reference allele (higher exposure) and insATAA variant allele (lower exposure). Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G. 30100615 1449733034
SLCO1B1 rs11045873 A rosuvastatin metabolism/PK yes Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele T. 30100615 1449733054
SLCO1B1 rs11045874 C rosuvastatin metabolism/PK yes Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G. 30100615 1449733062
SLCO1B1 rs4149056 C methotrexate toxicity no Discontinuation due to adverse effects. Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T. 27217051 1449164807
SLCO1B1 rs11045879 C methotrexate toxicity no Discontinuation due to adverse effects. Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T. 27217051 1449164813
SLCO1B1 rs2306283 A methotrexate toxicity no Discontinuation due to adverse effects. Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G. 27217051 1449164819
SLCO1B1 rs4149056 TT fluvastatin efficacy yes Response was determined as lower percentage change in total cholesterol (WMD: - 2.98; 95% CI: - 5.12 to - 0.84; P = 0.006, with no evidence of heterogeneity) and LDL (WMD: - 5.58; 95% CI: - 10.64 to - 0.52; P = 0.031, with significant heterogeneity). Genotype TT is associated with decreased response to fluvastatin as compared to genotypes CC + CT. 30363031 1450361642
SLCO1B1 rs2306283 AA fluvastatin efficacy no Response determined as percentage change in total cholesterol (WMD: 1.82; 95% CI:- 0.48 to 4.12; P = 0.121; with no evidence of heterogeneity) and LDL (WMD: - 0.59; 95% CI: - 8.65 to 7.47; P = 0.886; with significant heterogeneity). Genotype AA is not associated with response to fluvastatin as compared to genotypes AG + GG. 30363031 1450361636
SLCO1B1 rs11045819 A grazoprevir PD yes for both AUC0-24 and Cmax. Allele A is associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele C. 31250727 1450934575
SLCO1B1 rs2306283 G grazoprevir PD no Allele G is not associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele A. 31250727 1450934582
SLCO1B1 SLCO1B1*1, SLCO1B1*15 *15 pitavastatin metabolism/PK yes SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1. 23007012 1450814783
SLCO1B1 SLCO1B1*15, SLCO1B1*5 *5 + *15 paclitaxel metabolism/PK yes as measured by time above threshold concentration. PM/IM (one or two copies of *5 or *15) = 12.12 h, NM (*1/*1) = 10.15 h, SLCO1B1 *5 + *15 is associated with increased exposure to paclitaxel in women with Breast Neoplasms. 30520341 1450186374
SLCO1B1 rs4149056 C grazoprevir PD yes for both AUC0-24 and Cmax. Allele C is associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele T. 31250727 1450934565
SLCO1B1 rs4149056 CC + CT atazanavir / ritonavir metabolism/PK yes Patients were treated with the drug combination and plasma concentrations of both drugs were measured. Genotypes CC + CT is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotype TT. 31124411 1450415756
SLCO1B1 rs4149057 T methotrexate metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C. 29791011 1450045251
SLCO1B1 rs11045872 G methotrexate metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A. 29791011 1450045205
SLCO1B1 rs11045879 C methotrexate metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T. 29791011 1450045181
SLCO1B1 rs4149056 C ritonavir metabolism/PK no No significant association between this variant and trough concentrations of ritonavir in HIV patients treated with lopinavir/ritonavir. Variant referred to in the paper as 521T>C. Allele C is not associated with trough concentration of ritonavir in men with HIV Infections as compared to allele T. 20078617 1451114660
SLCO1B1 rs2306283 G letermovir metabolism/PK no No significant association between this variant and letermovir pharmacokinetics. Allele G is not associated with exposure to letermovir as compared to allele A. 31022310 1451105120
SLCO1B1 rs11045819 A lopinavir metabolism/PK no No significant association between this variant and trough concentrations of lopinavir or ritonavir in HIV patients treated with lopinavir/ritonavir. Variant referred to in the paper as 463C>A. Allele A is not associated with trough concentration of lopinavir or ritonavir in men with HIV Infections as compared to allele C. 20078617 1451114672
SLCO1B1 rs4149056 CC + CT lopinavir metabolism/PK yes Trough concentrations of lopinavir were significantly increased in patients with the CT genotype compared to TT and in the CC genotype compared to CT. Patients were treated with lopinavir/ritonavir, but no corresponding increase in trough concentrations was observed with ritonavir. Variant referred to in the paper as 521T>C. Genotypes CC + CT are associated with increased trough concentration of lopinavir in men with HIV Infections as compared to genotype TT. 20078617 1451114623
SLCO1B1 rs2306283 AA rocuronium efficacy yes Patients with the AA genotype had lower clinical duration of the initial dose (p=0.000 for AA vs AG and AA vs GG), lower clinical duration of the maintenance dose (p=0.011 for AA vs AG and p=0.025 for AA vs GG) and shorter recovery time (p=0.038 for AA vs AG and p=0.043 for AA vs GG) as compared to those with the AG or GG genotype. However, this allele was no longer significant in multivariable stepwise regression analysis. Genotype AA is associated with decreased response to rocuronium as compared to genotypes AG + GG. 25279974 1444934938
SLCO1B1 rs2306283 GG atorvastatin efficacy no While, on average, total cholesterol, triglycerides, and LDL-C concentrations decreased with simvastatin or atorvastatin treatment, the amount of decrease was not associated with this SNP. This lack of association remained when studied as a haplotype with rs4149056. Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG. 23263738 1183681948
SLCO1B1 rs2306283 A tacrolimus metabolism/PK no This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients. Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G. 29318894 1449163277
SLCO1B1 rs2306283 AA + AG lopinavir metabolism/PK no Genotypes AA + AG is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype GG. 27142945 1447986111
SLCO1B1 rs2306283 AA mycophenolic acid metabolism/PK no Concentrations measured as trough blood drug concentrations. Genotype AA is associated with decreased concentrations of mycophenolic acid in people with lung transplantation as compared to genotypes AG + GG. 26307985 1448100023
SLCO1B1 rs4149056 CT pravastatin metabolism/PK yes Patients with the CT genotype had significantly lower plasma Cmax, AUC and drug half-life. This variant was described as 521T>C. Genotype CT is associated with increased metabolism of pravastatin in children with Transplantation as compared to genotype TT. 16722833 982043158
SLCO1B1 rs2306283 G azathioprine efficacy no No significant association between this variant and survival post-transplantation or development of acute cellular rejection, lymphocytic bronchiolitis or chronic lung allograft dysfunction (CLAD). Allele G is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele A. 30992538 1451101338
SLCO1B1 rs2306283 G lopinavir metabolism/PK no No significant association between this variant and trough concentrations of lopinavir or ritonavir in HIV patients treated with lopinavir/ritonavir. Variant referred to in the paper as 388A>G. Allele G is not associated with trough concentration of lopinavir or ritonavir in men with HIV Infections as compared to allele A. 20078617 1451114666
SLCO1B1 rs4149056 CT conjugated estrogens efficacy no No association between genotype and change in symptom scores for hot flashes, insomnia or total symptoms following hormonal therapy was observed. Genotype CT is not associated with response to conjugated estrogens in women with Menopause as compared to genotype TT. 29738412 1449311443
SLCO1B1 rs4149056 CC + CT SN-38 dosage yes Where SN-38 is the active metabolite of irinotecan. Carriers of the C allele had a significantly increased area under the concentration curve (AUC) of SN-38 compared to T homozygotes. Genotypes CC + CT are associated with increased dose of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT. 18221820 981794122
SLCO1B1 rs2306283 GG rosuvastatin metabolism/PK yes This effect was only considered "marginally significant" by the authors and only seen in the subset of white individuals, and not observed in the different groups of Asian individuals. Genotype GG is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotype AA. 16198652 1449733021
SLCO1B1 rs4149056 C methotrexate metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T. 29791011 1450045245
SLCO1B1 rs2306283 AA + AG capecitabine efficacy yes Patients were split into two groups based on treatment. One group received irinotecan, fluorouracil, and leucovorin, and the other group received irinotecan and capecitabine. Patients carrying the A allele showed significantly greater rapid response rate, progression free survival, and irinotecan-related time to treatment failure as compared to patients with the GG genotype. In addition, when combined with rs1051266, patients carrying the A allele for this SNP and homozygous for the G allele at rs1051266 had significantly higher rapid response rates than patients with any other combination of genotypes. Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG. 24143213 1183697518
SLCO1B1 rs2306283 AA + AG mycophenolic acid metabolism/PK yes Clearance refers to oral clearance. A total of 166 plasma concentrations were available for population modeling. Mycophenolic acid PK was described as a time lagged two compartment model with first-order absorption and elimination and kinetics in accordance with sustained drug release (flip-flop). During covariate model building using step-wise covariate modeling (SCM) several covariates, including multiple genetic polymorphisms, produced a significant decrease in objective function value (OFV). Only rs2306283 and rs3832043 remained significant in the full covariate model, which included effect size. The two polymorphisms also remained significant in the backwards elimination model. Genotypes AA + AG is associated with decreased clearance of mycophenolic acid in people with Kidney Transplantation as compared to genotype GG. 25163792 1184755622
SLCO1B1 rs2306283 G rosuvastatin metabolism/PK not stated The authors compared PK parameters of rosuvastain between a Caucasian group (22) a Chinese (17), Filipino (19), Indian (16), Korean (23), Vietnamese(16), and Japanese (25) groups as well as a pooled "Asian" group. Similar genotype frequencies were observed across groups except an Indian subset who were TT. Only one Caucasian was CC. Exposure to rosuvastatin (as measured by AUC(0-t) and C max) was not affected by genotype. Allele G is not associated with exposure to rosuvastatin in healthy individuals as compared to allele A. 25630984 1444693888
SLCO1B1 rs2900478 A hmg coa reductase inhibitors efficacy yes Carriers of this variant respond to statins with a 1.6% smaller LDL-C lowering effect per minor allele compared with non-carriers. Allele A is associated with decreased response to hmg coa reductase inhibitors as compared to allele T. 25350695 1184997439
SLCO1B1 rs4149015 AG pravastatin "efficacy","metabolism/PK" yes The comparison was really done by haplotype- comparing three *17 carriers with 38 non-*17 carriers. *17 also contains rs2306283 and rs4149056. This is short-term response- a single dose of 40 mg/person. Plasma lathosterol concentration and lathosterol to cholesterol concentration ratio were measured. Genotype AG is associated with decreased response to pravastatin as compared to genotype GG. 15864131 769146231
SLCO1B1 rs4149032 CC isoniazid metabolism/PK yes This variant is associated with decreased AUC of isoniazid at week 8. Genotype CC is associated with decreased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes CT + TT. 30779340 1450807585
SLCO1B1 rs4149032 TT letermovir metabolism/PK yes The TT genotype was significantly associated with a decreased letermovir AUC compared to CC or CT subjects. However, the authors note that this change in AUC is not considered to be clinically meaningful. Genotype TT is associated with decreased exposure to letermovir as compared to genotypes CC + CT. 31022310 1451105105
SLCO1B1 rs4149056 CC + CT nateglinide metabolism/PK no Only subjects with the GG genotype at SLCO1B1 position 388 (rs2306283) were recruited to eliminate any effect from this allele. Subjects were put into 4 groups. The reference group was CYP2C9 *1/*1 + SLCO1B1 521TT. The other three groups were: CYP2C9 *1/*3 + SLCO1B1 521TT, CYP2C9 *1/*1 + SLCO1B1 521TC/CC, and CYP2C9 *1/*3 + SLCO1B1 521TC. Each group was found to have significantly higher AUCs and lower clearances when compared to the reference group. The effect of this SNP (rs4149056) was only found when studied in tandem with CYP2C9. rs4149056 was not significant when studied alone. Genotypes CC + CT are associated with decreased metabolism of nateglinide in healthy individuals as compared to genotype TT. 22842957 982047462
SLCO1B1 rs4149056 CC atorvastatin efficacy no While, on average, total cholesterol, triglycerides, and LDL-C concentrations decreased with simvastatin or atorvastatin treatment, the amount of decrease was not associated with this SNP. This lack of association remained when studied as a haplotype with rs2306283. Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT. 23263738 1183681930
SLCO1B1 rs4149056 CC + CT capecitabine efficacy no Patients were split into two groups based on treatment. One group received irinotecan, fluorouracil, and leucovorin, and the other group received irinotecan and capecitabine. No association was found between this SNP and rapid response rate, progression free survival, or irinotecan-related time to treatment failure. Genotypes CC + CT are not associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype TT. 24143213 1183697527
SLCO1B1 rs4149056 CC + CT methotrexate metabolism/PK yes Carriers of at least one polymorphic SLCO1B1 rs4149056 allele had significantly higher methotrexate levels after 24 h (median of 2.30 micromol/l compared with 1.56 micromol/l for carriers of two wildtype alleles, P =0.003) and methotrexate AUC (median of 34.2 micromol h/l compared with 22.8 micromol h/l for carriers of two wild-type alleles, P= 0.001. Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT. 25098908 1184747687
SLCO1B1 rs4149056 C mycophenolic acid metabolism/PK no A total of 166 plasma concentrations were available for population modeling. Mycophenolic acid PK was described as a time lagged two compartment model with first-order absorption and elimination and kinetics in accordance with sustained drug release (flip-flop). During covariate model building using step-wise covariate modeling (SCM) several covariates, including multiple genetic polymorphisms, produced a significant decrease in objective function value (OFV). Only rs2306283 and rs3832043 remained significant in the full covariate model, which included effect size. The two polymorphisms also remained significant in the backwards elimination model. Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T. 25163792 1184755674
SLCO1B1 rs4149056 T rosuvastatin metabolism/PK not stated The authors compared PK parameters of rosuvastain between a Caucasian group (22) a Chinese (17), Filipino (19), Indian (16), Korean (23), Vietnamese(16), and Japanese (25) groups as well as a pooled "Asian" group. Similar genotype frequencies were observed across groups except an Indian subset who were TT. Only one Caucasian was CC. Exposure to rosuvastatin (as measured by AUC(0-t) and C max) was higher in people with the CT genotype compared to TT genotype regardless of ethnic groups (except in the Filipino group) and does not explain the inter-ethnic variation in rosuvastatin exposure in Asian populations as compared to Caucasians. Geometric mean Cmax Caucasian CT =16.99 versus TT =9.84 and Cmax Pooled Asian group CT=27.90 versus TT =19.67. Geometric mean AUC(0-t) Caucasian CT =165.7 versus TT =98.4 and AUC(0-t) Pooled Asian group CT =247.9 versus TT = 181.1. Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C. 25630984 1444693880
SLCO1B1 rs4149056 CT rosuvastatin metabolism/PK not stated 1) Caucasians AUC0-t (ng*h/mL): Geometric mean (95% CI) AND Cmax (ng/mL): Geometric mean (95% CI) 2) Chinese AUC0-t (ng*h/mL): Geometric mean (95% CI) AND Cmax (ng/mL): Geometric mean (95% CI) 3) Japanese AUC0-t (ng*h/mL): Geometric mean (95% CI) AND Cmax (ng/mL): Geometric mean (95% CI) Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT. 25673568 1447989994
SLCO1B1 rs4149056 TT methotrexate metabolism/PK yes In patients with the rs4948496 CT+TT genotype, those with the TT genotype had lower serum methotrexate levels, as compared to those with the CT or CC genotype. Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT. 24712521 1296666350
SLCO1B1 rs4149056 CT simvastatin acid metabolism/PK not stated This variant significantly affect CLSH/VSA (apparent SV-to-SVA hydrolysis clearance). Individuals heterozygous (TC) for the rs4149056 SNP have approximately 44% decreased SVA clearance and 46% decreased SVA volume of distribution compared to homozygous wild-type subjects. SV: simvastatin; SVA:simvastatin acid. Genotype CT is associated with decreased clearance of simvastatin acid as compared to genotype TT. 24598718 1184754854
SLCO1B1 rs4149056 TT atazanavir dosage yes Randomized, controlled trial in which patients were placed into an atazanavir pharmacogenetically-directed dosing arm or a standard dosing arm. The pharmacogenetic arm took into account this variant, ABCB1 rs1045642 and PXR rs2472677. A greater percentage of patients in the pharmacogenetic arm had target atazanavir concentrations. Genotype TT is associated with dose of atazanavir in people with HIV Infections. 26174719 1448260874
SLCO1B1 rs4149056 C simvastatin efficacy no 609 self-reported white and 335 self-reported African American men and women with baseline total serum cholesterol level between 160 and 400 mg/dL received 40 mg simvastatin daily for 6 weeks. Clinic visits occurred at 2-week intervals during the 6-week study. Allele C is not associated with response to simvastatin as compared to allele T. 28482130 1448624730
SLCO1B1 rs4149056 C rosiglitazone efficacy yes as measured by HbA1c reduction. Allele C is associated with increased response to rosiglitazone in people with Diabetes Mellitus as compared to allele T. 27271184 1448276427
SLCO1B1 rs4149056 TT ticagrelor "efficacy","metabolism/PK" no Genotype TT is not associated with response to ticagrelor in healthy individuals as compared to genotypes CC + CT. 28049954 1448531959
SLCO1B1 rs4149056 T pioglitazone efficacy no Allele T is not associated with response to pioglitazone in people with Diabetes Mellitus as compared to allele C. 27271184 1448276436
SLCO1B1 rs4149056 CC + CT edoxaban metabolism/PK no No significant difference in total plasma exposure (AUCinf), peak plasma exposure (Cmax), trough concentrations (C24), plasma exposure from the time of dosing to the last measurable concentration (AUClast), or plasma exposure up to 24 hours after dosing (AUC0-24) were seen between the genotype groups. This indicates that this SNP "does not influence edoxaban exposure". However, the authors state that exposure to the M4 metabolite is elevated in individuals with the CC or CT genotype as compared to the TT genotype, though they do not provide any statistical information, and state that it does not increase exposure in "a clinically meaningful way". Genotypes CC + CT is not associated with exposure to edoxaban in healthy individuals as compared to genotype TT. 27897269 1448525865
SLCO1B1 rs4149056 CT repaglinide metabolism/PK yes Higher Cmax CT genotype (66.46ng/mL) vs TT genotype (43.37 ng/mL); CT genotype not significantly, higher AUC (AUC0–8 and AUC0–8) vs. TT genotype; there was no significant difference in elimination half-life or time to peak plasma concentration. Genotype CT is associated with increased concentrations of repaglinide in healthy individuals as compared to genotype TT. 29748863 1449311234
SLCO1B1 rs4149056 TT repaglinide metabolism/PK yes who were co-administered irbesartan. Elimination half-life, time to peak plasma concentration were not associated with the genotype, but was associated with maximum repaglinide concentration, and area under the concentration time curve were associated. Genotype TT is associated with exposure to repaglinide in healthy individuals. 29748863 1449311406
SLCO1B1 rs4149056 CC + CT lopinavir metabolism/PK no Genotypes CC + CT are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype TT. 28718515 1448821812
SLCO1B1 rs4149056 CC + CT ritonavir metabolism/PK no Genotypes CC + CT are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype TT. 28718515 1448821830
SLCO1B1 rs4149056 C fluvastatin metabolism/PK yes This variant is significantly associated with increased area under the plasma concentration-time curve (AUC) of 3R,5S-fluvastatin and total fluvastatin (but not 3S,5R-fluvastatin) in the candidate gene study. Allele C is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele T. 30989645 1450823509
SLCO1B1 rs4149056 CC + CT letermovir metabolism/PK yes The C allele was significantly associated with an increased letermovir AUC compared to TT subjects. However, the authors note that this change in AUC is not considered to be clinically meaningful. Genotypes CC + CT are associated with increased exposure to letermovir as compared to genotype TT. 31022310 1451105100
SLCO1B1 rs4149056 C amprenavir metabolism/PK yes Association was significant in white patients treated with fosamprenavir only. Only 3 Hispanic patients carried the C allele, so statistical analysis could not be carried out. However, the authors note that these patients also tended to have low trough concentrations of amprenavir. Allele C is associated with decreased trough concentration of amprenavir in people with HIV Infections as compared to allele T. 23503447 1451115880
SLCO1B1 rs4149056 C saquinavir metabolism/PK no Allele C is not associated with trough concentration of saquinavir in people with HIV Infections as compared to allele T. 23503447 1451115920
SLCO1B1 rs4149056 C lopinavir metabolism/PK yes Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T. 32022294 1451116340
SLCO1B1 rs4149056 CC + CT rosuvastatin metabolism/PK no SLCO1B1 521T > C was also partially associated with a higher AUC of rosuvastatin in young subjects and a less pronounced increasing trend in elderly subjects (p > 0.05 for both). However, it was not statistically significant. Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT. 31857620 1451124180
SLCO1B1 rs4149081 G methotrexate metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A. 29791011 1450045187
SLCO1B1 rs113681054 CT ar c124910xx metabolism/PK no Trend seen in the AUC (p = 0.093) but no significant difference seen in Cmax, tmax, t1/2, and CL/F. Genotype CT is associated with increased exposure to ar c124910xx in healthy individuals as compared to genotypes CC + TT. 28049954 1448531937
SLCO1B1 rs11045879 CC + CT methotrexate metabolism/PK yes Carriers of at least one polymorphic allele had significantly higher methotrexate levels after 24 h (median of 2.25 micromol/l compared with 1.70 micromol/l for carriers of two wild-type alleles, P =0.017) as well as methotrexate AUC (median of 31.9 micromol h/l compared with 26.8 micromol h/l for carriers of two wild-type alleles, P =0.011). Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT. 25098908 1184747694
SLCO1B1 rs113681054 C ticagrelor metabolism/PK no Comparing the diplotypes, no significant difference seen in Cmax, tmax, t1/2, AUC or CL/F. Allele C is not associated with increased exposure to ticagrelor in healthy individuals as compared to allele T. 28049954 1448531946